Roche Holding AG (RHHBF)
OTCMKTS
· Delayed Price · Currency is USD
303.50
+18.80 (6.60%)
Dec 23, 2024, 3:00 PM EST
Roche Holding AG Revenue
Roche Holding AG had revenue of 30.76B CHF in the half year ending June 30, 2024, a decrease of -9.27%. This brings the company's revenue in the last twelve months to 60.58B, down -3.12% year-over-year. In the year 2023, Roche Holding AG had annual revenue of 60.44B, down -8.16%.
Revenue (ttm)
60.58B CHF
Revenue Growth
-3.12%
P/S Ratio
n/a
Revenue / Employee
584.73K CHF
Employees
103,605
Market Cap
223.87B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
Dec 31, 2019 | 63.75B | 4.25B | 7.15% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sandoz Group AG | 10.11B |
Telix Pharmaceuticals Limited | 430.80M |
Elekta AB (publ) | 1.66B |
Ryman Healthcare Limited | 458.44M |
Verano Holdings Corp. | 897.57M |
Vireo Growth Inc. | 98.53M |
Medexus Pharmaceuticals Inc. | 104.76M |
Roche Holding AG News
- 1 day ago - Experts gather in Hong Kong to tackle liver cancer together - South China Morning Post
- 5 days ago - Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits - Benzinga
- 5 days ago - Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study - The Wall Street Journal
- 5 days ago - Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study - WSJ
- 5 days ago - Roche, Prothena miss main goal in mid-stage trial for Parkinson’s drug - Seeking Alpha
- 5 days ago - Roche Halts Development of SPK-8011 Amid Strategic Gene Therapy Focus - GuruFocus
- 5 days ago - Roche's Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson's disease - GlobeNewsWire
- 5 days ago - Genentech's Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson's Disease - Business Wire